Generics provide at least 95% of the pharmacological basic utility. However, now massive supply bottlenecks are threatening, because manufacturers are shutting down production, writes Jobst Landgrebe, Managing Director of the consulting firm Cognotekt, in the Standpoint. Due to fixed prices and discount contracts, manufacturers could not pass on their increased costs.

by Jobst Landgrebe

published on November 07, 2022